Krnić Z, Bradamante V
Biomedical Department, Research Institute PLIVA, Zagreb, Republic of Croatia.
Arzneimittelforschung. 1997 Aug;47(8):910-3.
The effect of chronic treatment with the non-selective beta-blocker oxprenolol (CAS 6452-71-7) administered orally in two different doses (15 or 30 mg/kg/day for 6, 10 and 12 weeks) on plasma cholinesterase (PChE) activity and on the plasma level of triglyceride and total cholesterol were studied in normal rats. In all treated groups a significant increase (approximately 27-51%) of PChE activity was obtained (p < 0.05 vs. control group). The plasma concentration of total cholesterol was significantly increased as well (21-48%, p < 0.05 vs. control) but oxprenolol exerted no significant effect on plasma triglyceride levels. The increase of enzyme activity and total cholesterol were not time- or dose-dependent. According to these results which showed a direct relationship between PChE activity and total cholesterol it is supposed that the increase of enzyme activity is initially due to the action of oxprenolol on total cholesterol metabolism but that it does not have a direct effect on the enzyme. The results contribute to the hypothesis that PChE plays a role in lipoprotein metabolism although this has not yet been proven.
在正常大鼠中,研究了口服两种不同剂量(15或30毫克/千克/天,持续6周、10周和12周)的非选择性β受体阻滞剂氧烯洛尔(CAS 6452-71-7)进行长期治疗对血浆胆碱酯酶(PChE)活性以及甘油三酯和总胆固醇血浆水平的影响。在所有治疗组中,PChE活性均显著增加(约27%-51%)(与对照组相比,p<0.05)。总胆固醇的血浆浓度也显著升高(21%-48%,与对照组相比,p<0.05),但氧烯洛尔对血浆甘油三酯水平没有显著影响。酶活性和总胆固醇的增加与时间或剂量无关。根据这些结果显示PChE活性与总胆固醇之间存在直接关系,推测酶活性的增加最初是由于氧烯洛尔对总胆固醇代谢的作用,但它对该酶没有直接影响。这些结果支持了PChE在脂蛋白代谢中起作用的假说,尽管这尚未得到证实。